Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

Research and development expenses for the third quarter of 2009 decreased to $1.5 million from $1.6 million in 2008, due mainly to lower costs associated with OGX-427. For the nine months ended September 30, 2009 research and development expenses increased to $6.8 million from $3.6 million in 2008. The increase was primarily due to OGX-011 and OGX-427 manufacturing-related costs incurred in the first nine months of 2009, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first nine months of 2008 was a Scientific Research and Development (SRED) claim, which offset R&D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company as a result of the reverse takeover, SRED claims can now only be applied against taxes payable.

General and administrative expenses for the third quarter decreased to $0.9 million from $1.0 million in 2008, due mainly to lower legal and accounting fees incurred in 2009. For the nine months ended S
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015  Centrillion Technologies, a genomic ... from the National Human Genome Research Institute, ... (NIH). The grant will help fund the ... of breakthrough genomic technologies, including phased sequencing ... Centrillion has been developing this transformative and ...
(Date:4/17/2015)... 2015 CIO Review ( http://www.cioreview.com ) ... Most Promising Pharma and Life Science Technology Solution Providers ... compliance software platform for life sciences companies. , ... panel of experts and members of CIO Review’s editorial ... Platform has been on our radar for some time ...
(Date:4/17/2015)... 2015  Guggenheim Securities, the investment banking and capital ... of William Tanner as a Managing Director ... will start work at Guggenheim in May 2015 in ... "Bill brings a wealth of biotech experience, ... and highly acclaimed healthcare team," said Matthew Johnson ...
(Date:4/17/2015)... Global Stem Cells Group has ... 2015 April 27 - 29, 2015 in Boston. This ... areas of stem cell research including applications, biology, medicine, ... medicine. , The conference will address recent developments ... research in stem cell therapies, regenerative medicine, tissue engineering, ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3
... 3 Caliper Life,Sciences, Inc. (Nasdaq: CALP ... 26th Annual Healthcare Conference will be webcast on ... Hrusovsky, President and CEO of,Caliper, will be providing ... can be accessed at, http://www.metameetings.com/webcasts/jpmorgan/healthcare08/ . An archived,presentation ...
... MEDX ) announced today that it is scheduled ... 10:30 a.m. ET on Tuesday, January,8, 2008. The event ... the,Investor Relations section of the Medarex Web site at ... be available following the event., About Medarex, ...
... Mass., Jan. 3 Mersana, a cancer therapeutics,company, ... as Chairman of,the Company,s Board of Directors. Mr. ... a significant record of accomplishment over a,30-year industry ... welcome Boyd Clarke as Chairman of our Board,of ...
Cached Biology Technology:Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... University biologist has been awarded over $2.3 million from ... of the human pathogen chlamydia in hopes of finding ... disease in the United States. David E. Nelson, ... Arts and Sciences, Department of Biology, and researchers in ...
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... buzz of the golden-winged warbler,s song might not sound like ... population of this little, gray songbird with bright yellow patches ... since 1966. And, as of yet, it remains unprotected by ... dire situation for the warbler, and Ronald Canterbury wants people ...
Cached Biology News:In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics 2In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics 3To drive infections, a hijacking virus mimics a cell's signaling system 2UC research: Saving habitat key to songbird's survival 2
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... polyclonal to FbxL7 The F ... which it was originally observed, is ... binds SKP1. F-box proteins are components ... called SCFs (SKP1, cullin, F-box proteins), ...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Biology Products: